PT3443075T - Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados - Google Patents
Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionadosInfo
- Publication number
- PT3443075T PT3443075T PT177356706T PT17735670T PT3443075T PT 3443075 T PT3443075 T PT 3443075T PT 177356706 T PT177356706 T PT 177356706T PT 17735670 T PT17735670 T PT 17735670T PT 3443075 T PT3443075 T PT 3443075T
- Authority
- PT
- Portugal
- Prior art keywords
- cell
- transgenic
- antigen receptor
- chimeric antigen
- related methods
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009261 transgenic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transplantation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323623P | 2016-04-15 | 2016-04-15 | |
| US201662323675P | 2016-04-16 | 2016-04-16 | |
| US201762461677P | 2017-02-21 | 2017-02-21 | |
| US201762462243P | 2017-02-22 | 2017-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3443075T true PT3443075T (pt) | 2022-12-16 |
Family
ID=59285314
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT221974447T PT4180519T (pt) | 2016-04-15 | 2017-04-14 | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
| PT177356706T PT3443075T (pt) | 2016-04-15 | 2017-04-14 | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT221974447T PT4180519T (pt) | 2016-04-15 | 2017-04-14 | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11377637B2 (OSRAM) |
| EP (3) | EP4628587A2 (OSRAM) |
| JP (1) | JP7058223B2 (OSRAM) |
| KR (3) | KR20240000616A (OSRAM) |
| CN (1) | CN109790517B (OSRAM) |
| AU (1) | AU2017250769B2 (OSRAM) |
| BR (1) | BR112018071199A2 (OSRAM) |
| ES (2) | ES2933961T3 (OSRAM) |
| PT (2) | PT4180519T (OSRAM) |
| SG (1) | SG11201808831TA (OSRAM) |
| WO (1) | WO2017180989A2 (OSRAM) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114058582A (zh) | 2015-01-26 | 2022-02-18 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| US11643668B2 (en) | 2015-06-17 | 2023-05-09 | The Uab Research Foundation | CRISPR/Cas9 complex for genomic editing |
| WO2016205680A1 (en) * | 2015-06-17 | 2016-12-22 | The Uab Research Foundation | Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
| CA3001008A1 (en) | 2015-10-05 | 2017-04-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| CN108601821B (zh) * | 2015-10-05 | 2023-09-19 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| EP3371301A4 (en) | 2015-11-04 | 2019-06-26 | Fate Therapeutics, Inc. | METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS |
| CN115806940A (zh) * | 2015-11-04 | 2023-03-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| CA3020330A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| PT4180519T (pt) | 2016-04-15 | 2025-09-04 | Memorial Sloan Kettering Cancer Center | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
| AU2017347637B2 (en) * | 2016-10-19 | 2024-02-15 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| GB2607227B (en) * | 2016-10-27 | 2023-05-10 | Intima Bioscience Inc | Viral methods of T cell therapy |
| CA3058807A1 (en) | 2017-04-03 | 2018-10-11 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| IL270361B2 (en) | 2017-05-01 | 2025-04-01 | Univ Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| MX2019015188A (es) | 2017-06-15 | 2020-08-03 | Univ California | Inserciones de adn no virales orientadas. |
| WO2019005957A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE |
| US20200216515A1 (en) * | 2017-07-26 | 2020-07-09 | Cellectis | Methods of antigen-dependent chimeric antigen receptor (car) immune cell selection |
| AU2018355587B2 (en) | 2017-10-27 | 2023-02-02 | The Regents Of The University Of California | Targeted replacement of endogenous T cell receptors |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| KR102828999B1 (ko) * | 2018-02-11 | 2025-07-04 | 메모리얼 슬로안 케터링 캔서 센터 | 비-hla 제한된 t 세포 수용체 및 이의 용도 |
| SG11202007513PA (en) * | 2018-02-16 | 2020-09-29 | Kite Pharma Inc | Modified pluripotent stem cells and methods of making and use |
| US20200224160A1 (en) * | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| AU2019253562B2 (en) * | 2018-04-09 | 2025-11-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions comprising a viral vector for expression of a transgene and an effector |
| WO2019200122A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
| WO2019204397A1 (en) * | 2018-04-17 | 2019-10-24 | Wake Forest University Health Sciences | Methods and compositions for th9 cell mediated cancer treatment |
| US20210207174A1 (en) * | 2018-05-25 | 2021-07-08 | The Regents Of The University Of California | Genetic engineering of endogenous proteins |
| JP2021525530A (ja) | 2018-06-01 | 2021-09-27 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
| TW202015719A (zh) | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| CN110616188B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种通用型car-t细胞及其制备方法和应用 |
| US12359169B2 (en) | 2018-06-20 | 2025-07-15 | Shanghai Longyao Biotechnology Inc., Ltd. | Universal CAR-T cell and preparation method and use thereof |
| EP3817763B1 (en) * | 2018-07-03 | 2025-09-03 | SOTIO Biotech Inc. | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| EP3845638A4 (en) * | 2018-07-26 | 2022-05-11 | Kyoto University | METHOD OF PRODUCTION OF A CELL DELIVERED BY A RECEPTOR GENE OF A FOREIGN ANTIGEN |
| BR112021001694A2 (pt) | 2018-08-14 | 2021-05-04 | Sotio, LLC | polipeptídeos do receptor de antígeno quimérico em combinação com moléculas de metabolismo trans que modulam o ciclo de krebs e seus usos terapêuticos |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| MX2021006968A (es) | 2018-12-12 | 2021-10-13 | Kite Pharma Inc | Antígeno quimérico y receptores de las células t, y métodos de uso. |
| PT3898946T (pt) * | 2018-12-19 | 2023-05-09 | Inst Curie | Células t invariantes associadas a mucosa (mait) que expressam recetores de antigénio quiméricos |
| EP3917546A4 (en) * | 2019-02-01 | 2023-03-08 | KSQ Therapeutics, Inc. | GENE REGULATORY COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| AU2020226401A1 (en) * | 2019-02-18 | 2021-10-14 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| EP3934668A1 (en) | 2019-03-06 | 2022-01-12 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with self-driving chimeric antigen receptors |
| BR112021019368A2 (pt) | 2019-03-29 | 2021-12-07 | Hoffmann La Roche | Método para produzir fcrn biotinilado no terminal c |
| MX2021012054A (es) * | 2019-04-11 | 2022-01-18 | Fate Therapeutics Inc | Reconstitución de cd3 en ipsc y células efectoras inmunitarias modificadas. |
| MX2021013223A (es) | 2019-05-01 | 2022-02-17 | Juno Therapeutics Inc | Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos. |
| EP3969482A1 (en) * | 2019-05-16 | 2022-03-23 | University of Washington | Lockr-mediated recruitment of car t cells |
| BR112021025401A2 (pt) * | 2019-06-19 | 2022-02-01 | Hoffmann La Roche | Métodos para produzir um anticorpo trivalente, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante, composição e método para produzir uma célula de mamífero recombinante |
| AU2020315796A1 (en) | 2019-07-19 | 2022-02-24 | Memorial Hospital For Cancer And Allied Diseases | Fusion polypeptide for immunotherapy |
| AU2020318781A1 (en) | 2019-07-23 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Immune cells defective for SUV39H1 |
| CN111826353B (zh) * | 2019-07-24 | 2024-03-26 | 浙江煦顼技术有限公司 | 调节t细胞功能和反应的方法 |
| WO2021061832A1 (en) * | 2019-09-23 | 2021-04-01 | Regents Of The University Of Minnesota | Genetically-edited immune cells and methods of therapy |
| CN114765991A (zh) * | 2019-09-25 | 2022-07-19 | 小利兰·斯坦福大学董事会 | 非色素睫状上皮细胞特异性启动子 |
| SG10201909544YA (en) * | 2019-10-11 | 2021-05-28 | Nat Univ Singapore | Genetically Modified T Cells And Uses Thereof |
| AR120469A1 (es) * | 2019-11-13 | 2022-02-16 | Crispr Therapeutics Ag | Proceso de fabricación para hacer células t que expresen receptores de antígeno quiméricos |
| WO2021095012A1 (en) * | 2019-11-13 | 2021-05-20 | Crispr Therapeutics Ag | Methods of manufacturing car-t cells |
| CN113122576A (zh) * | 2019-12-31 | 2021-07-16 | 博雅辑因（北京）生物科技有限公司 | 一种通用型truck-t细胞、其制备方法以及用途 |
| EP4084815A1 (en) * | 2020-01-02 | 2022-11-09 | Edity Therapeutics Ltd. | Delivery compositions and methods |
| CA3171369A1 (en) * | 2020-02-28 | 2021-09-02 | Wisconsin Alumni Research Foundation | Nonviral generation of genome edited chimeric antigen receptor t cells |
| JP2023518295A (ja) * | 2020-03-20 | 2023-04-28 | オルナ セラピューティクス インコーポレイテッド | 環状ｒｎａ組成物及び方法 |
| GB202006903D0 (en) * | 2020-05-11 | 2020-06-24 | Adaptimmune Ltd | Modified iPSCs |
| JP2023532347A (ja) * | 2020-06-29 | 2023-07-27 | セル メディカ，インコーポレイテッド | キメラ抗原受容体の緊張性シグナル伝達を減少させる方法および組成物 |
| WO2022011065A1 (en) * | 2020-07-07 | 2022-01-13 | The Nemours Foundation | Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer |
| CA3190266A1 (en) | 2020-07-30 | 2022-02-03 | Institut Curie | Immune cells defective for socs1 |
| AU2021320556A1 (en) * | 2020-08-07 | 2023-03-09 | Neogene Therapeutics B.V. | Methods to enrich genetically engineered T cells |
| JP2023544337A (ja) * | 2020-09-30 | 2023-10-23 | ブイオーアール バイオファーマ インコーポレーテッド | キメラ抗原受容体発現系 |
| WO2022118310A1 (en) * | 2020-12-01 | 2022-06-09 | Lepton Pharmaceuticals Ltd. | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4019538A1 (en) * | 2020-12-22 | 2022-06-29 | Charité - Universitätsmedizin Berlin | Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes |
| MX2023010641A (es) | 2021-03-11 | 2024-02-07 | Mnemo Therapeutics | Peptidos neoantigénicos tumorales y usos de los mismos. |
| KR20230172630A (ko) | 2021-03-11 | 2023-12-22 | 므네모 테라퓨틱스 | 종양 네오 항원성 펩타이드 |
| KR20240006721A (ko) | 2021-03-11 | 2024-01-15 | 엥스띠뛰 퀴리 | 막 형질 전환 네오 안티젠 펩타이드 |
| US20240271095A1 (en) * | 2021-05-14 | 2024-08-15 | Appia Bio, Inc. | Production of engineered t cells from stem cells |
| EP4413031A1 (en) | 2021-10-06 | 2024-08-14 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
| EP4416292A2 (en) | 2021-10-14 | 2024-08-21 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| JP2024541859A (ja) * | 2021-10-14 | 2024-11-13 | アッピア バイオ，インコーポレイティド | 幹細胞の遺伝子改変による複数のｔ細胞受容体を有するｔ細胞 |
| US20250000907A1 (en) * | 2021-11-22 | 2025-01-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Engineered immune cells with reduced sirt6 expression |
| EP4456910A1 (en) | 2021-12-28 | 2024-11-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| JP2025504882A (ja) | 2022-01-21 | 2025-02-19 | ムネモ・セラピューティクス | Ｒｎａによるｓｕｖ３９ｈ１発現の調節 |
| CN115304679B (zh) * | 2022-01-21 | 2024-07-16 | 郑州大学第一附属医院 | 一种促进t细胞分化的限制型car及其应用 |
| WO2023178227A2 (en) * | 2022-03-17 | 2023-09-21 | University Of Florida Research Foundation, Incorporated | Chimeric lactate receptor engineered t cells |
| WO2023225670A2 (en) * | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| EP4573114A2 (en) | 2022-08-19 | 2025-06-25 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| EP4580604A2 (en) * | 2022-09-02 | 2025-07-09 | OncoSenX, Inc. | Compositions and methods for in vivo expression of chimeric antigen receptors |
| BE1031219B1 (fr) | 2022-12-28 | 2024-07-29 | Quidditas Sa | Composition, cellules immunitaires la comprenant et utilisation de ces dernières |
| WO2025096594A2 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof |
| WO2025096560A1 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
| WO2025213167A1 (en) * | 2024-04-05 | 2025-10-09 | Roswell Park Cancer Institute Corporation | Complement signaling as a t-cell checkpoint in the tumor microenvironment (tme) |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| DK1409646T3 (da) | 2000-12-19 | 2012-08-06 | Altor Bioscience Corp | Transgene dyr omfattende et humaniseret immunsystem |
| IL162111A0 (en) | 2001-12-22 | 2005-11-20 | 4Antibody Ag | Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo |
| EP1321477B1 (en) | 2001-12-22 | 2004-10-13 | 4-Antibody AG | Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2005026718A1 (en) | 2003-08-28 | 2005-03-24 | Five Prime Therapeutics, Inc. | Stem cell libraries |
| US20110213288A1 (en) | 2007-04-23 | 2011-09-01 | The Board Of Regents, The University Of Texas System | Device And Method For Transfecting Cells For Therapeutic Uses |
| JP5271901B2 (ja) | 2007-06-11 | 2013-08-21 | タカラバイオ株式会社 | 特異的遺伝子発現方法 |
| ES2627552T3 (es) | 2008-12-04 | 2017-07-28 | Sigma Aldrich Company | Edición de genoma en ratas usando nucleasas con dedos de cinc |
| JP2013500018A (ja) * | 2009-07-24 | 2013-01-07 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー | ゲノム編集のための方法 |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| JP6050230B2 (ja) | 2010-07-21 | 2016-12-21 | サンガモ バイオサイエンシーズ， インコーポレイテッド | Ｈｌａ遺伝子座の修飾のための方法及び組成物 |
| NO2748201T3 (OSRAM) | 2011-08-23 | 2018-05-12 | ||
| WO2013158309A2 (en) | 2012-04-18 | 2013-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Non-disruptive gene targeting |
| HUE064187T2 (hu) | 2012-05-25 | 2024-02-28 | Cellectis | Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására |
| RS59199B1 (sr) | 2012-05-25 | 2019-10-31 | Univ California | Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta |
| EP3763810A3 (en) * | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| KR102064230B1 (ko) | 2013-02-15 | 2020-01-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
| CA3185368A1 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t cells derived from pluripotent stem cells |
| JP6578271B2 (ja) | 2013-04-17 | 2019-09-18 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫抑制ＴＧＦ−βシグナルコンバーター |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| AU2014273490B2 (en) | 2013-05-29 | 2019-05-09 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system |
| WO2015140347A1 (en) | 2014-03-21 | 2015-09-24 | Cellectis | Engineering mammalian genome using dna-guided argonaute interference systems (dais) |
| KR20200138445A (ko) | 2014-04-24 | 2020-12-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
| AU2015255675A1 (en) | 2014-05-09 | 2016-12-01 | Research Foundation Of The City University Of New York | TCR(alpha)-LCR-derived gene regulatory cassettes |
| US9970001B2 (en) * | 2014-06-05 | 2018-05-15 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease design |
| HUE049776T2 (hu) | 2014-06-06 | 2020-10-28 | Regeneron Pharma | Módszerek és készítmények egy célzott lókusz módosítására |
| AU2015317370A1 (en) | 2014-09-19 | 2017-03-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| WO2016081924A1 (en) | 2014-11-20 | 2016-05-26 | Duke University | Compositions, systems and methods for cell therapy |
| EP4269601A3 (en) | 2015-03-27 | 2024-01-10 | President and Fellows of Harvard College | Modified t cells and methods of making and using the same |
| WO2016166268A1 (en) | 2015-04-17 | 2016-10-20 | Cellectis | Engineering animal or plant genome using dna-guided argonaute interference systems (dais) from mesophilic prokaryotes |
| DE212016000094U1 (de) * | 2015-05-15 | 2017-12-18 | Oru Kayak, Inc. | Zusammenfaltbares Kajak mit großem Cockpit |
| CN108024544B (zh) * | 2015-07-13 | 2022-04-29 | 桑格摩生物治疗股份有限公司 | 用于核酸酶介导的基因组工程化的递送方法及组合物 |
| IL257105B (en) | 2015-07-31 | 2022-09-01 | Univ Minnesota | Modified cells and methods of therapy |
| CA3001008A1 (en) | 2015-10-05 | 2017-04-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| CN108601821B (zh) | 2015-10-05 | 2023-09-19 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| CN115806940A (zh) | 2015-11-04 | 2023-03-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| EP3371301A4 (en) | 2015-11-04 | 2019-06-26 | Fate Therapeutics, Inc. | METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS |
| EP3377523A4 (en) | 2015-11-19 | 2019-06-19 | The Regents of The University of California | CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF |
| US20190241910A1 (en) | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
| CU24649B1 (es) | 2016-03-19 | 2023-02-13 | Exuma Biotech Corp | Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos |
| CA3020330A1 (en) | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| PT4180519T (pt) | 2016-04-15 | 2025-09-04 | Memorial Sloan Kettering Cancer Center | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados |
-
2017
- 2017-04-14 PT PT221974447T patent/PT4180519T/pt unknown
- 2017-04-14 ES ES17735670T patent/ES2933961T3/es active Active
- 2017-04-14 SG SG11201808831TA patent/SG11201808831TA/en unknown
- 2017-04-14 CN CN201780037351.1A patent/CN109790517B/zh active Active
- 2017-04-14 KR KR1020237042980A patent/KR20240000616A/ko active Pending
- 2017-04-14 EP EP25181439.8A patent/EP4628587A2/en active Pending
- 2017-04-14 WO PCT/US2017/027601 patent/WO2017180989A2/en not_active Ceased
- 2017-04-14 KR KR1020227029151A patent/KR102614675B1/ko active Active
- 2017-04-14 EP EP22197444.7A patent/EP4180519B1/en active Active
- 2017-04-14 BR BR112018071199-3A patent/BR112018071199A2/pt active Search and Examination
- 2017-04-14 KR KR1020187032919A patent/KR102437015B1/ko active Active
- 2017-04-14 JP JP2018554069A patent/JP7058223B2/ja active Active
- 2017-04-14 PT PT177356706T patent/PT3443075T/pt unknown
- 2017-04-14 US US16/091,494 patent/US11377637B2/en active Active
- 2017-04-14 EP EP17735670.6A patent/EP3443075B1/en active Active
- 2017-04-14 ES ES22197444T patent/ES3039670T3/es active Active
- 2017-04-14 AU AU2017250769A patent/AU2017250769B2/en active Active
-
2022
- 2022-05-25 US US17/824,650 patent/US12404316B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240000616A (ko) | 2024-01-02 |
| EP3443075A2 (en) | 2019-02-20 |
| KR102614675B1 (ko) | 2023-12-19 |
| WO2017180989A3 (en) | 2017-12-14 |
| US20190119638A1 (en) | 2019-04-25 |
| CN109790517B (zh) | 2023-05-02 |
| ES2933961T3 (es) | 2023-02-15 |
| ES3039670T3 (en) | 2025-10-23 |
| CA3020923A1 (en) | 2017-10-19 |
| SG11201808831TA (en) | 2018-11-29 |
| EP4180519B1 (en) | 2025-06-11 |
| EP4628587A2 (en) | 2025-10-08 |
| US20220411753A1 (en) | 2022-12-29 |
| KR20220123325A (ko) | 2022-09-06 |
| KR20180133496A (ko) | 2018-12-14 |
| JP7058223B2 (ja) | 2022-04-21 |
| KR102437015B1 (ko) | 2022-08-29 |
| WO2017180989A2 (en) | 2017-10-19 |
| BR112018071199A2 (pt) | 2019-02-12 |
| US12404316B2 (en) | 2025-09-02 |
| EP3443075B1 (en) | 2022-09-28 |
| US11377637B2 (en) | 2022-07-05 |
| PT4180519T (pt) | 2025-09-04 |
| JP2019511236A (ja) | 2019-04-25 |
| EP4180519A1 (en) | 2023-05-17 |
| AU2017250769B2 (en) | 2022-07-14 |
| CN109790517A (zh) | 2019-05-21 |
| AU2017250769A1 (en) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT4180519T (pt) | Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados | |
| IL273956A (en) | Methods for preparing cells expressing chimeric antigen receptor | |
| IL263626A (en) | Chimeric antigen receptors and methods of use | |
| PT3294764T (pt) | Composições de recetores de antigénios quiméricos | |
| IL254254A0 (en) | chimeric antigen receptor | |
| SG10202012157QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| DK3166968T3 (da) | Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler | |
| SG10201913245UA (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
| PT3674315T (pt) | Recetores de antigénios quiméricos, composições e métodos | |
| GB201503742D0 (en) | Chimeric antigen receptor | |
| SG11201808411RA (en) | Chimeric antigen and t cell receptors and methods of use | |
| SG11201606790XA (en) | Chimeric antigen receptor | |
| GB201607968D0 (en) | Chimeric antigen receptor | |
| SG11201705293WA (en) | Methods of making chimeric antigen receptor-expressing cells | |
| GB201610512D0 (en) | Chimeric antigen receptor | |
| SG11201701297WA (en) | Antibodies and chimeric antigen receptors specific for cd19 | |
| ZA201906321B (en) | Chimeric antigen receptor | |
| SG11201800872QA (en) | Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed | |
| GB201709508D0 (en) | Chimeric antigen receptor | |
| IL266950B1 (en) | γδ t cells expressing a chimeric antigen receptor for use in immunotherapy | |
| GB201519900D0 (en) | Chimeric antigen receptor | |
| GB201721421D0 (en) | Chimeric antigen receptor | |
| GB201810451D0 (en) | Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof | |
| HK40004398A (en) | Chimeric antigen receptor t cell compositions | |
| GB201612844D0 (en) | Chimeric antigen receptor |